Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) Sees Significant Growth in Short Interest

Posted by ABMN Staff on Mar 21st, 2025

Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS – Get Free Report) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 700 shares, a growth of 16.7% from the February 13th total of 600 shares. Based on an average daily volume of 17,100 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are sold short.

Tema Cardiovascular and Metabolics ETF Stock Up 0.3 %

Tema Cardiovascular and Metabolics ETF stock opened at $30.13 on Friday. The company has a market capitalization of $69.30 million, a PE ratio of 32.63 and a beta of 0.93. The firm has a fifty day simple moving average of $30.03 and a two-hundred day simple moving average of $31.61. Tema Cardiovascular and Metabolics ETF has a twelve month low of $28.56 and a twelve month high of $36.03.

Institutional Trading of Tema Cardiovascular and Metabolics ETF

An institutional investor recently raised its position in Tema Cardiovascular and Metabolics ETF stock. Sterling Investment Advisors Ltd. boosted its holdings in Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS – Free Report) by 5.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 167,703 shares of the company’s stock after purchasing an additional 9,008 shares during the period. Tema Cardiovascular and Metabolics ETF makes up 1.2% of Sterling Investment Advisors Ltd.’s portfolio, making the stock its 24th largest position. Sterling Investment Advisors Ltd. owned 7.29% of Tema Cardiovascular and Metabolics ETF worth $4,842,000 as of its most recent SEC filing.

Tema Cardiovascular and Metabolics ETF Company Profile

(Get Free Report)

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive.